Latest News
February 19, 2025

Actinic Keratosis drug receives FDA Approval for which CBCC had conducted the Clinical Endpoint study in the US!

  Actinic Keratosis drug receives FDA Approval for which CBCC had conducted the Clinical Endpoint study in the US! Type of application: 505 (j) ANDA Therapeutic Area: Dermatology Scope: End-to-end clinical trial management Country of trial execution: USA CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION Manoj Vyas Dr. Sandeep Singh Jaimeen Vanparia Avanish Mishra, Ph.D. Sanjeev Ganatra Harakh Shah, PMP® Nikhil Gandhi Tapan Shah Kinnari Gandhi RQAP-GCP Dr. Praveen Choudhary Nikunj Patel Ankit Parikh Ajit Upadhyaya Ankit Pandav Devang Pandya Jay Vyas Udayan Vyas